Tom Reeves, President and CEO Closely-held Ripple Therapeutics, a recent spinout from Interface Biologics, is pursuing a $25-million series A financing to complete a Phase 2 trial of IBE-814 IVT, a dexamethasone prodrug...

David Fischel, Chairman and CEO Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping...

Nancy White, CEO Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized...

Tom Isett, Strategic Advisor and Board Member iBio (NYSE American:IBIO) is continuing its transition from a licensing business to a manufacturing services provider and developer of proprietary biologics. Central to the...

Dr. Bill Williams, President and CEO BriaCell Therapeutics (OTCQB:BCTXD; TSXV:BCT) believes its Phase 2 clinical program in advanced breast cancer, which includes an ongoing combination study of its Bria-IMT with immune...

Kane Biotech (TSXV:KNE) has completed a major transformation during the past year, relaunching its animal health business, expanding into human health, raising non-dilutive financing, and hiring a new executive team...

Closely-held Squarex will be seeking an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 as a steppingstone for pivotal testing of its SQX770 topical treatment for the prevention of recurrent cold sores...

Artelo Biosciences (NASDAQ:ARTL) is gearing up to begin a UK-based Phase 1b/2a study of its cannabinoid agonist drug candidate, ART 27.13, which has the potential to stimulate cancer patients’ appetite and promote...